Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0263

View Point

Predicting risk  of disease and therapeutic resistance for patients with Hepatocellular Carcinoma.

Dimitrios Schizas, MD, PhD.

Affiliation: Dimitrios Schizas, (DS), 1st Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.



Prognosis of hepatocellular carcinoma (HCC) remains poor. The slow progress in understanding the molecular mechanisms driving tumorigenesis, metastasis and therapeutic resistance explains the low rates of early detection and overall survival. This editorial summarizes the latest advances and challenges of next-generation sequencing (NGS) in developing robust biomarkers to predict the individualized risk and therapeutic response of HCCs.

(Citation: Gastric & Breast Cancer 2017; 12(2): 85-90)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 August 2017